Citeline Connect

Frequently Asked Questions (FAQs)

What is a clinical trial?

Through clinical research, scientists and doctors can determine whether a new medical strategy, drug, or device is safe and effective for people. New treatments cannot be discovered without clinical trials, which rely on potential trial participants like you to evaluate the safety and effectiveness of these treatments. Participation in a clinical trial is voluntary. Trial participants should have the intention to complete the trial, but they may leave the trial at any time after they join.

What does a typical clinical trial look like?

Clinical trials help determine the safety and effectiveness of treatments. A research plan, also called a protocol, is created before the trial starts. The protocol describes who can join the trial, what treatments the participants will receive, what questions the researchers will seek to answer, how long the trial will last, and how participant privacy and safety will be protected during the trial.

A clinical trial may compare a new treatment to a standard treatment option that is already available, to a placebo (an identical-looking treatment with no active ingredient), or to no intervention at all. Before you decide to join a clinical trial, the trial team will explain all of the trial details.

What is a Phase 3 clinical trial?

When new drugs are being studied as a possible treatment for patients with a disease, they are tested in stages, or “phases.” If a drug is successful in Phase 1, it moves to Phase 2. If it is successful in Phase 2, it moves to Phase 3.

Drugs that enter Phase 3 trials have already been studied in other clinical trials. Researchers have gathered initial information about the safety of the drug already, usually in up to several hundred people. Phase 3 trials usually include large numbers of participants. Some Phase 3 trials are conducted in multiple countries and include thousands of people. Phase 3 trials are used to collect even more information about how safe a drug is and how well it works.

How can I check to see if I’m eligible for this trial?

You can check if you are potentially eligible for a trial by completing a set of screening questions. You can find these on this website by clicking the “Match to a Trial” button.

Can I quit the trial at any time?

Trial volunteers have the right to drop out of the trial at any time for any reason or no reason at all. The trial doctor or sponsor also has the right to discontinue a trial volunteer at any time for the participant’s safety or if the participant no longer meets the trial requirements.

What personal information is collected about me for the trial?

The trial doctor and other site staff will collect your personal information. This may include:

Your name, address, and telephone number
Your age, sex, and ethnic and racial background
Your lifestyle information
Your medical history details
Your trial treatment and your response to this treatment
Data resulting from testing your biological samples

Learn more about ongoing clinical trials evaluating investigational compounds to improve and expand treatments for patients with inflammatory and autoimmune conditions, such as Hidradenitis Suppurativa and Prurigo Nodularis.

Match to a Trial

Join the Incyte Community

Join the Incyte Community to receive updates on news about Incyte, including information on newly enrolling trials. The Incyte Community enables you to stay informed & prepared to contribute to research you care about.

Join Incyte Community

About IAI

Incyte’s research and development efforts in Dermatology are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to develop treatments that restore normal immune function to the body. Many inflammatory conditions such as Hidradenitis Suppurativa (HS) and Pruirgo Nodularis (PN) are affected by a dysregulation of the JANUS kinase (JAK)/ signal transducer and activator of transcription (STAT) pathway.

Currently, Incyte is exploring the potential of JAK inhibition for additional indications with a high unmet medical need that results from an abnormal immune system response, such as HS and PN.

We strive to identify and develop therapies to stop uncontrolled inflammation, help restore normal immune function, and bring the body closer to equilibrium.

Match to a trial

Hidradentis Suppurtiva

Hidradenitis suppurativa (HS) is a long-term skin condition that causes painful bumps, boils and/or abscesses to develop under the skin. It usually develops in areas where there is hair or where the skin rubs together, such as the armpits, groin, between the buttocks, and under the breasts. People with HS can have repeated outbreaks of HS, which can leave scars on the skin. As HS gets more severe, these bumps, boils and/or abscesses can rupture or leak and cause scarring.

Researchers are looking for other ways to treat HS. In these trials, researchers are studying an investigational drug called “povorcitinib”, which is a JAK1 inhibitor taken by mouth.  JAK1 inhibitors are a type of medication that interfere with signals of the body that are thought to cause inflammation. This, in turn, reduces the inflammation that is linked with HS; with less inflammation, symptoms of your HS such as pain, discharge, and itch are also reduced, and your HS lesions are expected to get better.  

PRURIGO NODULARIS

Prurigo nodularis (PN) is a long-term skin condition that causes itchy bumps called “nodules” on the skin. These nodules can appear in any part of the body, but most often appear in areas where you can scratch, such as the arms, legs, and trunk. Aside from severe itching, people with PN may also feel painful stinging and burning. These symptoms can affect a person’s quality of life.

In these trials, researchers are investigating the use of the JAK inhibitor, ruxolitinib cream for the (topical) treatment of PN to determine if it is effective in relieving itch and healing the nodules.

Are you a licensed Healthcare Professional?

Frequently Asked Questions (FAQs)

Join the Incyte Community

About IAI

Hidradentis Suppurtiva

PRURIGO NODULARIS